George Harb is Vice President of Regenerative Biology at Cellino Biotech, an iPSC platform company located in Cambridge, MA.
He has experience in pluripotent stem cell-based therapies. Most recently as Sr. Director at Vertex Pharmaceuticals, where he led stem cell and islet research programs
From 2015 to 2021 George led cell therapy R&D at Semma Therapeutics and later Vertex Pharmaceuticals following the acquisition of Semma in 2019. Semma was founded in 2015 to develop stem cell derived islet cell replacement therapies for Type 1 diabetes. Prior to joining Semma, George was at the Novartis Institute for Biomedical Research in San Diego, CA developing small molecule inducers of human beta cell proliferation and survival.